These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 15741800)
1. Determination of prothombinase activation after adding human purified prothrombin to human clot: comparison of hirudin, an activated factor II inhibitor, with DX9065a, an activated factor X inhibitor, on clot-associated thrombin and on prothrombin activation. Meddahi S; Bara L; Fessi H; Samama MM Blood Coagul Fibrinolysis; 2005 Mar; 16(2):125-33. PubMed ID: 15741800 [TBL] [Abstract][Full Text] [Related]
2. Is the inhibition of both clot-associated thrombin and factor Xa more clinically relevant than either one alone? Meddahi S; Samama MM Blood Coagul Fibrinolysis; 2009 Apr; 20(3):207-14. PubMed ID: 19657318 [TBL] [Abstract][Full Text] [Related]
3. Pharmacologic modulation of thrombin generation associated with human clots by human purified antithrombin alone or in the presence of low molecular weight heparin or unfractionated heparin. Meddahi S; Bara L; Fessi H; Samama MM Blood Coagul Fibrinolysis; 2000 Jan; 11(1):51-9. PubMed ID: 10691099 [TBL] [Abstract][Full Text] [Related]
4. Inhibition of clot-bound and free (fluid-phase thrombin) by a novel synthetic thrombin inhibitor (Ro 46-6240), recombinant hirudin and heparin in human plasma. Gast A; Tschopp TB; Schmid G; Hilpert K; Ackermann J Blood Coagul Fibrinolysis; 1994 Dec; 5(6):879-87. PubMed ID: 7893925 [TBL] [Abstract][Full Text] [Related]
6. Role of thrombin compared with factor Xa in the procoagulant activity of whole blood clots. Prager NA; Abendschein DR; McKenzie CR; Eisenberg PR Circulation; 1995 Aug; 92(4):962-7. PubMed ID: 7641380 [TBL] [Abstract][Full Text] [Related]
7. DX9065a, an Xa inhibitor, inhibits prothrombin-induced A549 lung adenocarcinoma cell proliferation. Nakata M; Kanekura S; Maruyama I Cancer Lett; 1998 Jan; 122(1-2):127-33. PubMed ID: 9464501 [TBL] [Abstract][Full Text] [Related]
8. Laboratory assays for the evaluation of recombinant hirudin. Walenga JM; Hoppensteadt D; Koza M; Wallock M; Pifarre R; Fareed J Haemostasis; 1991; 21 Suppl 1():49-63. PubMed ID: 1894197 [TBL] [Abstract][Full Text] [Related]
9. Importance of factor Xa in determining the procoagulant activity of whole-blood clots. Eisenberg PR; Siegel JE; Abendschein DR; Miletich JP J Clin Invest; 1993 May; 91(5):1877-83. PubMed ID: 8486759 [TBL] [Abstract][Full Text] [Related]
10. Heparin and low molecular weight heparins inhibit prothrombinase formation but not its activity in plasma. Ofosu FA; Lormeau JC; Craven S; Dewar L; Anvari N Thromb Haemost; 1994 Dec; 72(6):862-8. PubMed ID: 7740455 [TBL] [Abstract][Full Text] [Related]
11. The anticoagulant mechanism of action of recombinant hirudin (CGP 39393) in plasma. Lindhout T; Blezer R; Hemker HC Thromb Haemost; 1990 Nov; 64(3):464-8. PubMed ID: 2096492 [TBL] [Abstract][Full Text] [Related]
12. Fibrin-targeted recombinant hirudin inhibits fibrin deposition on experimental clots more efficiently than recombinant hirudin. Bode C; Hudelmayer M; Mehwald P; Bauer S; Freitag M; von Hodenberg E; Newell JB; Kübler W; Haber E; Runge MS Circulation; 1994 Oct; 90(4):1956-63. PubMed ID: 7923685 [TBL] [Abstract][Full Text] [Related]
13. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. Weitz JI; Hudoba M; Massel D; Maraganore J; Hirsh J J Clin Invest; 1990 Aug; 86(2):385-91. PubMed ID: 2384594 [TBL] [Abstract][Full Text] [Related]
14. Role of clot-associated (-derived) thrombin in cell proliferation induced by fibrin clots in vitro. Gandossi E; Lunven C; Berry CN Br J Pharmacol; 2000 Mar; 129(5):1021-7. PubMed ID: 10696104 [TBL] [Abstract][Full Text] [Related]
15. Qualitative description of factors involved in the retraction and lysis of dilute whole blood clots and in the aggregation and retraction of platelets. Taylor FB; Müller-Eberhard HJ J Clin Invest; 1970 Nov; 49(11):2068-85. PubMed ID: 4248913 [TBL] [Abstract][Full Text] [Related]
16. The effect of fibrin clots and clot-bound thrombin on the development of platelet procoagulant activity. Kumar R; Béguin S; Hemker HC Thromb Haemost; 1995 Sep; 74(3):962-8. PubMed ID: 8571330 [TBL] [Abstract][Full Text] [Related]
17. Recombinant hirudin as a periprocedural antithrombotic in coronary angioplasty for unstable angina pectoris. Hafner G; Rupprecht HJ; Luz M; Terres W; Schindel F; Friesen HJ; Heinrichs H; Jessel A; Meyer J; Prellwitz W Eur Heart J; 1996 Aug; 17(8):1207-15. PubMed ID: 8869862 [TBL] [Abstract][Full Text] [Related]
18. Distinct effects of recombinant desulfatohirudin (Revasc) and heparin on plasma levels of fibrinopeptide A and prothrombin fragment F1.2 in unstable angina. A multicenter trial. Rao AK; Sun L; Chesebro JH; Fuster V; Harrington RA; Schwartz D; Gallo P; Matos D; Topol EJ Circulation; 1996 Nov; 94(10):2389-95. PubMed ID: 8921778 [TBL] [Abstract][Full Text] [Related]
19. Decreased thrombin activity of fibrin clots prepared in cord plasma compared with adult plasma. Patel P; Weitz J; Brooker LA; Paes B; Mitchell L; Andrew M Pediatr Res; 1996 May; 39(5):826-30. PubMed ID: 8726236 [TBL] [Abstract][Full Text] [Related]
20. Activation of human prothrombin by highly purified human factors V and X-a in presence of human antithrombin. Rosenberg JS; Beeler DL; Rosenberg RD J Biol Chem; 1975 Mar; 250(5):1607-17. PubMed ID: 1112820 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]